CSL to separate vaccine business, cut jobs
On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” and “highly irrational.”
Previous Post
Corticosteroid Use in Duchenne Muscular Dystrophy Management
Next Post
Viking shares sink as obesity pill misses expectations in key study
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago